-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (AD) is the leading cause of dementia worldwide
So far, the only effective treatment for cognitive or memory impairment symptoms that occur in diseases such as Alzheimer's disease is to use a wide range of drugs that increase acetylcholine
A recent study unexpectedly found that anti-The epilepsy drug Levetiracetam may be effective!
epilepsyIn fact, among Alzheimer's disease patients, an estimated 10-22% will have seizures, while another 22-54% will have asymptomatic seizures
This study was published in JAMA Neurology on September 27.
JAMA
FDA
Screening
Main findings
Source: doi:10.
Patients receiving levetiracetam showed a trend of improvement in cognitive function, but when the patients were divided into asymptomatic patients with active epilepsy and asymptomatic patients, patients with asymptomatic active epilepsy benefited significantly from drug treatment
In this randomized clinical trial, levetiracetam was well tolerated.
Levetiracetam is a pyrrolidone derivative, and its chemical structure is not related to existing antiepileptic drugs
Levetiracetam is a pyrrolidone derivative, and its chemical structure is not related to existing antiepileptic drugs
Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, Mizuiri D, Honma SM, Venkateswaran N, Koestler M, Zhang W, Mucke L, Howell MJ, Possin KL, Kramer JH, Boxer AL, Miller BL, Nagarajan SS, Kirsch HE.
Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, Mizuiri D, Honma SM, Venkateswaran N, Koestler M, Zhang W, Mucke L, Howell MJ, Possin KL, Kramer JH, Boxer AL, Miller .
BL, the SS Nagarajan, Kirsch HE Effect ofLevetiracetamoN Cognition of Alzheimer Disease in Patients With and Without Epileptiform With the Activity: A Randomized Clinical Trial.
Levetiracetam JAMA 2021 on Sep 27.
A Neurol.
DOI:.
10.
1001 / jamaneurol.
2021.
3310
in this message
